Back to Browse Journals » Open Access Emergency Medicine » Volume 2

Strategies for the prevention and treatment of sudden cardiac death

Authors Emad F Aziz, Fahad Javed, Balaji Pratap, et al

Published 10 December 2010 Volume 2010:2 Pages 99—114


Review by Single-blind

Peer reviewer comments 2

Emad F Aziz, Fahad Javed, Balaji Pratap, Eyal Herzog
The Advanced Cardiac Admission Program, St Luke's-Roosevelt Hospital Center, University Hospital of Columbia University, College of Physicians and Surgeons, New York, NY, USA

Abstract: Cardiovascular diseases account for 40% of all deaths in the West. Sudden cardiac death (SCD) is a major health problem affecting over 300,000 patients annually in the United States alone. Presence of coronary artery disease (CAD), usually in the setting of diminished left ventricular ejection fraction, is still the single major risk factor for SCD. Additionally, acute myocardial ischemia, structural cardiac defects, anomalous coronary arteries, cardiomyopathies, genetic mutations, and ventricular arrhythmias are all attributed to SCD, demonstrating the perplexity of this condition. With the recent advancements in cardiovascular medicine, the incidence of SCD is expected to increase steeply as the prevalence of CAD and heart failure is uprising in general population. Considering SCD, the major challenge confronting contemporary cardiology, multiple strategies for prevention against SCD have been developed. β-blockers have been shown to reduce the risk of SCD, whereas implantable cardioverter–defibrillator devices are found to be effective at terminating the malignant arrhythmias. In recent years, multiple clinical trials were carried out to identify patients who may benefit from preventive intervention, including medical therapy and automatic cardioverter–defibrillator implantations. This review article provides insight into the advanced strategies for the prevention and treatment of SCD based on the data available in medical literature to date.

Keywords: risk stratification, sudden cardiac death, prevention, treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments

Trudo F, Kern DM, Davis JR, Tunceli O, Zhou S, Graham EL, Strange C, Williams SA

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2055-2066

Published Date: 28 September 2015

Regulation of protein–protein interactions using stapled peptides

Robertson NS, Jamieson AG

Reports in Organic Chemistry 2015, 5:65-74

Published Date: 12 August 2015

Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data

D’Urzo AD, Kerwin EM, Chapman KR, Decramer M, DiGiovanni R, D’Andrea P, Hu H, Goyal P, Altman P

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1599-1612

Published Date: 11 August 2015

Palliative care in COPD: an unmet area for quality improvement

Vermylen JH, Szmuilowicz E, Kalhan R

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1543-1551

Published Date: 6 August 2015

Sedation with dexmedetomidine in the intensive care setting

Gerlach AT, Murphy CV

Open Access Emergency Medicine 2011, 3:77-85

Published Date: 10 November 2011